Axsome Therapeutics (AXSM) free cash flow

Free cash flow · fiscal 2025
-$93.89M

Axsome Therapeutics (AXSM) generated free cash flow of -$93.89M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$128.68M. Figures as of 18 Nov 2026, 11:42 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
-$93.89M
Highest on record
-$7.46Mfiscal 2015
Lowest on record
-$145.66Mfiscal 2023
Fiscal years on record
112015–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Axsome Therapeutics free cash flow, in more detail

Across the 11 fiscal years on record (2015–2025), the highest was -$7.46M in fiscal 2015 and the lowest -$145.66M in fiscal 2023.

History · 11 fiscal years

Free cash flow by fiscal year

Axsome Therapeutics free cash flow, year by year

Axsome Therapeutics (AXSM) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025-$93.89M—
2024-$128.68M—
2023-$145.66M—
2022-$117.21M—
2021-$108.53M—
2020-$78.50M—
2019-$46.39M—
2018-$30.09M—
2017-$26.48M—
2016-$21.39M—
2015-$7.46M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Axsome Therapeutics and comparable companies
CompanyFree cash flowFiscal year
Immunovant IMVT-$407.32M2026
Axsome Therapeutics AXSM-$93.89M2025
Chemed CHE$325.48M2025
Oruka Therapeutics ORKA-$88.42M2025
Arrowhead Pharmaceuticals ARWR-$283.94M2026
MSA Safety MSA$295.43M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on AXSM

Axsome Therapeutics, figure by figure

Axsome Therapeutics (AXSM) overview: price, valuation and scorecardAll health care companies by market value

Axsome Therapeutics free cash flow: questions and answers

What is Axsome Therapeutics's free cash flow?

Axsome Therapeutics (AXSM) generated free cash flow of -$93.89M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$128.68M.

What are the highest and lowest free cash flow figures on record for Axsome Therapeutics?

Across the 11 fiscal years on record (2015–2025), the highest was -$7.46M in fiscal 2015 and the lowest -$145.66M in fiscal 2023.

How is Axsome Therapeutics's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Axsome Therapeutics it is on record here for 11 fiscal years, 2015 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Axsome Therapeutics (AXSM) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/AXSM/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.